Duo et al. (Duo et al. 2024) used ML‐based virtual screening to identify novel compounds targeting SOS1 in the RAS signaling pathway, revealing promising inhibitors with unique binding modes and favorable drug‐like properties for RAS‐driven cancers. Here, SOS1 is linked to cancer.